The peptidyl-prolyl isomerase cyclophilin A (CypA) embraces an exposed, proline-rich loop on HIV-1 capsid (CA) and renders reverse transcription complexes resistant to an antiviral activity in human cells. A CypA fusion with TRIM5 that is unique to New World owl monkeys also targets HIV-1 CA, but this interaction potently inhibits infection. A similar block to HIV-1 infection in Old World monkeys is attributable to the ␣ isoform of the TRIM5 orthologue in these species. To determine whether HIV-1 restriction by Old World monkey TRIM5␣ is modulated by the CA-CypA interaction, RNA interference was used to disrupt CypA in cells from African green monkeys and rhesus macaques. HIV-1 infectivity increased in response to CypA knock-down to the same extent that it increased in response to TRIM5 knock-down. CypA knock-down eliminated the HIV-1 stimulatory effect of cyclosporin A (CsA), a competitive inhibitor of the CypA-CA interaction, or of CA mutants that block binding to CypA but caused no change in titer of retroviruses that don't interact with CypA. Simultaneous knock-down of both CypA and TRIM5 caused minimal additional increase in titer, suggesting that CypA inhibits HIV-1 replication in these cells because it is required for CA recognition by TRIM5␣. Finally, CsA increased HIV-1 titer in otherwise nonrestrictive feline cells but only after these cells were transduced with Old World monkey TRIM5␣. Thus, CypA is required for HIV-1 restriction by Old World monkey orthologues of TRIM5␣.
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restriction ͉ retrovirus ͉ capsid ͉ cyclosporin A ͉ RNA interference T he hydrophobic pocket of cyclophilin A (CypA) makes direct contact with HIV-1 capsid (CA) proline 90 and adjacent residues on the surface-exposed loop between ␣-helices IV and V (1) (2) (3) . This interaction can be disrupted experimentally by mutations that alter CA proline 90 or adjacent residues, by competitive inhibitors of the interaction [e.g., cyclosporin A (CsA)], by CypA knockout, or by CypA knock-down with RNA interference (2, (4) (5) (6) (7) . Each of these interventions inhibits HIV-1 infectivity in human cells, with the block occurring early, at the time of viral cDNA accumulation. Recent data have led to the hypothesis that, by binding to CA, CypA protects HIV-1 from a human antiviral restriction activity (8, 9) .
In contrast with the situation in humans, owl monkeys of the New World genus Aotus possess a potent HIV-1-specific inhibitor that is overcome by the same CA mutants, competitive inhibitors, or CypA-specific RNA interference that decrease HIV-1 infectivity in human cells (8, 10, 11) . This paradox was resolved by the discovery that owl monkey cells synthesize CypA as a fusion protein with TRIM5 (10, 11), a member of the tripartite motif family named for its RING, B-box, and coiledcoil domains (12) . The native function of TRIM5 is unknown, but its ability to serve as a target for E2 ubiquitylation in a RING-dependent manner (13) suggests that it acts as an E3 ubiquitin ligase in vivo. Whatever the TRIM5 antiviral mechanism, by binding to CA, the CypA domain of the owl monkey TRIM5-CypA fusion specifically targets HIV-1 for restriction.
HIV-1 replication in cells from several Old World monkeys also encounters a block before completion of reverse transcription (8, (14) (15) (16) (17) (18) , although TRIMCyp is not detected in these species (10, 11, 19) . This anti-HIV-1 activity instead requires the TRIM5 ␣ isoform (20) , in which a SPRY domain takes the place of CypA at the protein's C terminus and determines which particular viruses are susceptible to restriction (19) (20) (21) (22) (23) (24) (25) (26) . Nonetheless, HIV-1 determinants for sensitivity to restriction by Old World monkey TRIM5␣ map to the same region of CA where CypA binds (8, 16, (27) (28) (29) (30) (31) (32) (33) , and CsA has been reported to increase HIV-1 replication in Old World monkey cell lines (8, 31, 33) . These observations suggested a role for CypA in HIV-1 CA recognition by Old World monkey TRIM5␣ and prompted us to directly test this possibility.
Materials and Methods
Plasmid DNAs. pHIV-1 NL-GFP and pSIV MAC239-GFP (in which SIV denotes simian immunodeficiency virus) encode modified versions of the infectious clones HIV-1 NL4 -3 and SIV MAC239 . Both lack a functional env and express GFP instead of Nef (31). pCIG3N and pCIG3B, which express the N-tropic and B-tropic versions of murine leukemia virus (MLV) Gag͞Pol, and pCNCG, an MLV-derived vector expressing GFP, are described in refs. 34 and 35. Equine infectious anemia virus (EIAV) gag-pol vector pONY3.1 and GFP-packaging vector pONY8.0 are described in ref. 36 . pMD-G (37) encodes the envelope glycoprotein of the vesicular stomatitis virus (VSV G) that was used to pseudotype all viruses produced in this work. pCL-Eco (38) and p⌬R8.9 (37) encode the structural proteins for Moloney MLV and HIV-1, respectively. pMH (7, 10) and pSUPER.retro.puro (pSRP; OligoEngine, Seattle) are both murine stem cell virus (MSCV)-derived retroviral vectors designed for the expression of short hairpin RNAs (shRNAs). pMH-CypA147 expresses an shRNA targeting the human, rhesus, and African green monkey (AGM) CypA mRNAs, as described in refs. 7 and 10. The control plasmid, pMH-Luc, encodes an shRNA targeting luciferase (10) . pSRPshTRIM5 expresses small interfering RNA 3 (20) targeting TRIM5 mRNA but as a shRNA.
pCSW-ntCypA (7) bears human CypA cDNA with silent nucleotide changes that make it resistant to the CypA shRNA used. It was constructed by replacing GFP with ntCypA in the HIV-1-derived vector pCSGW (8) . To express TRIM5␣, we amplified cDNA from rhesus cells (FRhK4) and AGM cells (CV1) by using the following oligonucleotides: 5Ј-CGCTCGAGATGGCTTCTGGAATCCTG-GTTAATGTAAAGGAGGAGG-3Ј and 5Ј-GCGAATTCT-CACTTATCGTCGTCATCCTTGTAATCAGAGCTTGGT-GAGCACAG-3Ј. The product was cut with EcoR1 and XhoI and cloned into pMIP, a version of pMSCV-IRES-GFP (39) in which GFP is replaced by the puromycin resistance gene.
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Abbreviations: AGM, African green monkey; CsA, cyclosporin A; CypA, cyclophilin A; CA, capsid; MLV, murine leukemia virus; SIV, simian immunodeficiency virus; VSV G, vesicular stomatitis virus glycoprotein; shRNA, short hairpin RNA; EIAV, equine infectious anemia virus. ‡ To whom correspondence should be addressed. E-mail: jl45@columbia.edu. Cells, Drugs, and Antibodies. 293T, FRhK4, and Vero cells were used as before (7, 31) . CRFK cells were obtained from the American Type Culture Collection. CsA was prepared and used as described in ref. 31 . CypA was detected on Western blots with a rabbit polyclonal antibody (Biomol, Plymouth Meeting, PA). ␤-Actin was detected by a horseradish peroxidase-conjugated goat polyclonal antibody (Santa Cruz Biotechnology). Viral Challenges. FRhK4, Vero, or CRFK cells were plated at 30,000 cells in 0.4 ml per well of 24-well plates. Cells were infected the next day with HIV-1 NL-GFP , SIV MAC239-GFP , N-MLV, or B-MLV vectors. When CsA was used, it was added at the same time as the virus. Cell supernatants were replaced with fresh medium without drugs 16 h after infection. Cells were trypsinized and analyzed by flow cytometry 2 days after infection (31, 35) . Each infectivity experiment was repeated on at least two separate occasions.
Results

CypA Knock-Down Rescues HIV-1 Replication in Old World Monkey
Cells. AGM Vero cells were transduced with retroviruses bearing shRNA expression cassettes targeting either CypA or the irrelevant luciferase mRNA. The CypA shRNA decreased steadystate levels of CypA to the point where this protein was almost undetectable by Western blot (Fig. 1A) . VSV G-pseudotyped HIV-1 and SIV MAC239 reporter viruses were normalized by reverse transcriptase activity and used to challenge these cells. HIV-1 infectivity was Ͼ10-fold higher with the shRNA-CypA cells than with the control shRNA-Luc cells (Fig. 1B) . In contrast, shRNA-CypA did not alter the infectivity of SIV MAC239 , a virus that is relatively unrestricted (17) , or N-MLV (Fig. 1C) , a virus that is restricted as potently as HIV-1 in Vero cells (40) . Neither SIV MAC239 nor N-MLV encodes a CA that binds CypA (1). Similar, stimulatory effects on infectivity that were specific to HIV-1 were observed when CypA was knocked down in the rhesus macaque cell line FRhK4 (Figs. 3 and 4 and data not shown). Thus, CypA knock-down specifically increases HIV-1 infectivity in Old World monkey cells.
CypA Binding to CA Decreases HIV-1 Infectivity in Old World Monkey
Cells. To determine whether inhibition of HIV-1 infectivity by CypA in Old World monkey cells involves CypA interaction with HIV-1 CA, we examined the effect of CypA knock-down on two interventions that block CypA-CA interaction. CsA, a competitive inhibitor of the CA-CypA interaction (1), increased HIV-1 replication by 10-fold in the AGM cells expressing the control shRNA, but this effect was abolished by expression of the shRNA targeting CypA (Fig. 2A) . This finding demonstrates that CsA stimulates HIV-1 replication in Vero cells by means of effects on CypA. HIV-1 CA mutant G89V prevents interaction with CypA (41) and caused a 5-fold increase in HIV-1 replication in the control AGM cells but not in the CypA knock-down cells (Fig. 2B) . Taken together, these results indicate that CypA knock-down increases HIV-1 infectivity because it precludes HIV-1 CA from binding to CypA. Similar results with CsA and G89V were obtained by using rhesus macaque FRhK4 cells in which CypA had been knocked down (data not shown).
Reconstitution of CypA Restores HIV-1 Resistance to Macaque Cells in
Which CypA Had Been Knocked Down. In owl monkey cells, shRNAs targeting CypA disrupt expression of both CypA and TRIMCyp (10) . To demonstrate that CypA is the relevant target of the shRNA in the Old World monkey cells, we restored CypA protein to CypA knocked-down rhesus macaque FRhK4 cells (Fig. 3A) by transducing a CypA cDNA (ntCypA) that bears silent mutations in the RNA interference target sequence (10). Reconstitution of CypA protein to the shRNA-CypA cells decreased HIV-1 replication by 10-to 25-fold and restored the responsiveness of HIV-1 infectivity to CsA (Fig. 3B Right) . Thus, HIV-1 stimulation by the CypA shRNA indeed results from effects on CypA and not any of the 14 other cyclophilins in the mammalian genome that are capable of interacting with HIV-1 CA (1, 2, 6). Similar results were obtained by reconstituting CypA protein in the shRNA-CypA Vero cells (data not shown).
CypA accumulated to higher than normal levels when ntCypA was transduced into the control shRNA-Luc cells (Fig. 3A) . The elevated CypA levels had no significant effect on SIV MAC239 infectivity (data not shown) but significantly decreased HIV-1 replication when compared with cells synthesizing wild-type levels of CypA (Fig. 3B Left) . In addition, CsA enhanced HIV-1 replication 200-fold in the cells with elevated levels of CypA. Thus, the magnitude of HIV-1 restriction in rhesus macaque cells and the magnitude of CsA-mediated enhancement of HIV-1 replication both correlate with CypA protein levels.
HIV-1 Inhibition by CypA in Rhesus Macaque Cells Is TRIM5-Dependent.
To determine whether TRIM5␣ and CypA act independently to inhibit HIV-1 replication, rhesus macaque FRhK4 cells were first transduced with retroviruses bearing shRNAs targeting either CypA or luciferase. Each of these lines was then transduced a second time with shRNA targeting either TRIM5 or a control.
Compared with control cells, knock-down of either TRIM5 or CypA resulted in a Ͼ10-fold increase in HIV-1 infectivity (Fig.  4A) . Cells in which both CypA and TRIM5 were knocked down exhibited only an Ϸ2-fold additional increase in HIV-1 infectivity. The titer of SIV MAC239 , a virus that is relatively resistant to restriction by rhesus macaque TRIM5␣ (20, 23) , was not altered by CypA or TRIM5 knock-down (data not shown). EIAV does not encode a CA that interacts with CypA, but it is restricted by rhesus macaque TRIM5␣ (23) . As previously reported using human cells (23) , EIAV infectivity was modestly increased by knock-down of macaque TRIM5␣ (Fig. 4B) . In contrast, CypA knock-down, with or without TRIM5␣ knockdown, had no effect on EIAV infectivity (Fig. 4B) .
If TRIM5␣ and CypA acted independently to inhibit HIV-1 replication in rhesus macaque cells, then the effect of knocking down both factors within the same cell should have been additive, causing a greater increase in HIV-1 infectivity than we observed (Fig. 4A) . Further evidence that CypA and TRIM5␣ act within the same pathway to inhibit HIV-1 infectivity was provided by the fact that the magnitude enhancement of HIV-1 infection by CsA was reduced to the same extent in CypA knock-down, TRIM5 knock-down, and CypA͞TRIM5 double knock-down cells: Stimulation by CsA was 30-fold in the control cells and 3-fold in any of the three knock-down lines (data not shown). Taken together, the data here show that the mechanisms by which CypA and TRIM5␣ inhibit HIV-1 infectivity are clearly related.
Old World Monkey TRIM5␣ Renders HIV-1 Infection of Cat Cells
CsA-Responsive. Feline cells do not restrict HIV-1 infection (19, 22, 23) , apparently because they do not possess a TRIM5 orthologue. Consistent with a model in which CypA binding to CA modulates HIV-1 sensitivity to TRIM5␣-mediated restriction, HIV-1 infectivity in cat cells was not altered by CsA (Fig. 5) .
TRIM5␣ cDNAs from rhesus macaques or AGMs are sufficient to transfer potent HIV-1 restriction activity to cat cells (19, 22, 23) . When cat cells expressing TRIM5␣ cDNA from rhesus macaque FRhK4 cells or AGM CV-1 cells were challenged with HIV-1 at a fixed multiplicity of infection, CsA increased HIV-1 infectivity in a dose-dependent fashion (Fig. 5) . CsA had no effect on SIV MAC239 infectivity (Fig. 5) , even though cat cells expressing CV-1 TRIM5␣ restrict SIV MAC239 and HIV-1 to a comparable extent (ref. 23 and data not shown). Given that cyclosporine suppresses TRIM5-mediated restriction of HIV-1 in monkey cells by means of effects on CypA (Fig. 2 A) , it is reasonable to assume that suppression of monkey TRIM5-mediated restriction of HIV-1 in cat cells by cyclosporine also occurs by means of effects on CypA. Thus, these results confirm in a heterologous context that modulation of HIV-1 infectivity by CypA results from effects on virus susceptibility to TRIM5␣-mediated restriction.
Discussion
Evidence was presented here that, in cells from rhesus macaques and AGMs, CypA acts in trans to promote TRIM5␣-mediated restriction of HIV-1. Put another way, the anti-HIV-1 effect of CypA in these cells is TRIM5␣-dependent as well as transferable to a heterologous system by expressing rhesus macaque or AGM TRIM5␣ in otherwise nonrestrictive cat cells. Interestingly, CypA is also required for plant innate immunity to bacterial infection. The antibacterial resistance factor RPS2 is activated in Arabidopsis when Pseudomonas syringae injects the AvrRpt2 effector protease into the plant cytoplasm (42, 43) . AvrRpt2 protease activation requires an Arabidopsis orthologue of CypA (44) .
The effect of CypA on TRIM5␣-mediated restriction in Old World monkeys offers a potentially informative contrast to the effect of CypA in other primate species. In owl monkeys, CypA is synthesized as a fusion protein with TRIM5 (10, 11) . The CypA domain of the owl monkey fusion protein acts in cis to target the incoming virus for restriction, presumably because it binds directly to HIV-1 CA (11, 45) . The discovery of the owl monkey protein supplied an important clue to the importance of the SPRY domain, which substitutes for CypA at the C terminus of TRIM5␣ and is similarly required for binding to restrictionsensitive CA (46) .
In human cells, the effect of CypA seems to be the opposite of what we report here with Old World monkey cells. CypA increases HIV-1 infectivity in human cells (2, (4) (5) (6) (7) , possibly by protecting the virus from the human orthologue of TRIM5␣ (8, 9) . Given that TRIM5 orthologues heteromultimerize and suppress each others' retroviral restriction activity (11, 45) , it is interesting that coexpression of human TRIM5␣ seems to cancel out the stimulatory effect that CsA or CA-G89V mutants have on HIV-1 infectivity in the presence of Old World monkey TRIM5␣ (refs. 21, 25 , and 47 and data not shown). Ultimately, biochemical models for HIV-1 CA recognition by different TRIM5␣ orthologues will need to provide satisfactory explanation for the opposite effects of CypA in these different contexts. Species-specific differences in the SPRY domain determine which particular retroviruses a given TRIM5␣ orthologue will restrict (19) (20) (21) (22) (23) (24) (25) (26) . The effect of CypA on restriction activity might similarly be determined by species-specific differences in TRIM5␣. Most data, though, suggest that CypA does not directly regulate TRIM5␣ activity. For example, we show here that CypA does not alter the infectivity of a TRIM5␣-sensitive virus if that virus does not encode a CA that binds CypA. No interaction between CypA and TRIM5␣ was detected by using either the yeast two-hybrid system or coimmunoprecipitation, and the two proteins do not colocalize by fluorescence microscopy (data not shown). CypA regulates the subcellular distribution of zincfinger protein Zpr1p in Saccharomyces cerevisiae (48) , so it was hypothesized that CypA might also regulate TRIM5␣ localization. However, the subcellular distribution of TRIM5␣, as well as the formation of cytoplasmic bodies, was not altered by disruption of CypA (data not shown).
The data indicate, then, that CypA promotes TRIM5␣-mediated restriction of HIV-1 in Old World monkey cells by means of direct effects on CA. How might CypA promote the recognition of HIV-1 CA by TRIM5␣? Members of the cyclophilin family catalyze the cis-trans isomerization of peptidylprolyl bonds, a rate-limiting step for protein folding in vitro (49) (50) (51) (52) . HIV-1 CA is, in fact, the only mature folded protein shown to be a catalytic substrate of CypA (53) . In the absence of CypA, nearly 90% of the covalent bonds linking HIV-1 CA glycine 89 and proline 90 are in the trans conformation (54) . If TRIM5␣ only recognized the cis-isomer, then, by increasing the rate of isomerization, CypA would promote HIV-1 CA recognition and restriction by TRIM5␣.
Alternatively, CypA binding to HIV-1 CA, in the absence of catalysis, might be sufficient to trigger TRIM5␣ recognition. Binding to CypA might induce an allosteric change in CA, leading to exposure of an otherwise hidden TRIM5␣-binding surface. Or, the CypA-CA complex might form a composite surface that is required for association with TRIM5␣. The calcineurin-binding surface that is generated when the immunosuppressive drug CsA fills the hydrophobic pocket of CypA provides a precedent for the latter model (55) . 
